<DOC>
	<DOCNO>NCT01239459</DOCNO>
	<brief_summary>Primary Objective : - To determine effect severe renal impairment pharmacokinetic profile teriflunomide administer single 14 mg dose compare healthy subject Secondary Objective : - To assess tolerability teriflunomide administer single 14 mg dose subject severe renal impairment compare subject normal renal function .</brief_summary>
	<brief_title>Pharmacokinetic Tolerability Study 14 mg Single Dose Teriflunomide Subjects With Severe Renal Impairment</brief_title>
	<detailed_description>The total study duration per subject 11-15 week break follow : - Screening : 3 week - Hospitalization : 3 day ( admission 1 day prior study drug intake ) - Follow-up : 10 -12 week</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Cholestyramine Resin</mesh_term>
	<criteria>Inclusion criterion : Subjects renal impairment : Male subject 18 75 year age inclusive postmenopausal female 45 75 year age inclusive . Chronic severe renal impairment define CockroftGault formula ( creatinine clearance ( CLcr ) &lt; 30mL/min , require hemodialysis ) . Laboratory parameter within acceptable range subject renal impairment ; particular , hepatic enzyme ( ALT , AST ) bilirubin &lt; 2 x upper limit normal range neutrophil within normal range . Matched healthy subject : Male subject 18 75 year age inclusive postmenopausal female 45 75 year age inclusive , matched age . Body weight within 15 % body weight subject renal impairment match Body Mass Index 18.0 30.0 mg/kg2 inclusive . Certified healthy comprehensive clinical assessment ( detailed medical history complete physical examination ) . Normal renal function define CockroftGault formula ( creatinine clearance ( CLcr ) &gt; 80mL/min ) Laboratory parameter within normal range , unless Investigator considers abnormality clinically irrelevant healthy subject ; however serum creatinine , alkaline phosphatase , hepatic enzyme ( AST , ALT ) , bilirubin ( unless subject document Gilbert syndrome ) exceed upper limit normal range . Exclusion criterion : Subjects renal impairment : Uncontrolled clinically relevant cardiovascular , pulmonary , gastrointestinal , metabolic , hematological , neurological , psychiatric , systemic , ocular , gynecologic ( female ) infectious disease , sign acute illness . Active hepatitis , hepatic insufficiency . Acute renal failure ( de novo superimpose preexist chronic renal impairment ) , nephrotic syndrome . Subject require dialysis study . Any significant change chronic treatment medication within 14days inclusion . Any drug , could impact mechanism action , pharmacokinetic investigational product . Positive reaction Human Immunodeficiency Virus ( HIV ) test : antiHIV1 antibody , antiHIV2 antibody Positive result urine drug screen ( amphetamine / methamphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , opiates ) unless result secondary document medical prescription . Positive alcohol test . Man disagree use double barrier method contraception partner study . Matched healthy subject : Any history presence clinically relevant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic , hematological , neurological , psychiatric , systemic , ocular , gynecologic ( female ) , infectious disease , sign acute illness . For subject 50 year old : medication ( include St John 's Wort ) within 14 day inclusion , within 5 time elimination halflife pharmacodynamic halflife drug , whichever long , exception menopausal hormone replacement therapy . significant change chronic treatment medication within 14days inclusion . Any drug , could impact mechanism action , pharmacokinetic investigational product . Positive reaction follow test : hepatitis B surface ( HBs ) antigen , antihepatitis C virus ( antiHCV ) antibody , HIV1 antibody , antiHIV2 antibody . Positive result urine drug screen ( amphetamine / methamphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , opiates ) . Positive alcohol test . Man disagree use double barrier method contraception partner study The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>